Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Small Cell Lung Carcinoma 6Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 5Lung Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Sarcoma 2Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Dendritic Cell Sarcoma, Interdigitating 2Unspecified Adult Solid Tumor, Protocol Specific 1Thymoma 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Sezary Syndrome 1

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Metastatic NUT Carcinoma × Etoposide × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡